Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
ACCESSWIRE•04/11/2026•09:00 ET
0
Key Highlights
- ➤Lexaria (LEXX) signs agreement with unnamed pharmaceutical company for DehydraTECH evaluation
- ➤PharmCo will supply proprietary molecules for processing and evaluation using DehydraTECH
- ➤Successful evaluation could lead to a licensing agreement with traditional economic terms
- ➤Lexaria will disclose study outcomes and potential licensing decisions after initial evaluations
KELOWNA, BC / ACCESS Newswire / November 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical company ("PharmCo") to investigate Lexaria's DehydraTECH technology with one or more proprietary PharmCo molecules.
Today's announcement is separate from, and has no relationship with, Lexaria's two Material Transfer Agreements already existing with other pharmaceutical companies.
Get started
Create a free account to read the full story.